(2Z,4E,6Z,8Z)-N-丁基-3,7-二甲基-9-(2,6,6-三甲基-1-环己烯基)壬-2,4,6,8-四烯酰胺 | 33631-44-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: (2Z,4E,6Z,8Z)-N-丁基-3,7-二甲基-9-(2,6,6-三甲基-1-环己烯基)壬-2,4,6,8-四烯酰胺
• 英文名称: all-trans-N-butylretinamide
• 英文别名: N-(Butyl)retinamide；(2E,4E,6E,8E)-N-butyl-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide
• CAS: 33631-44-6
• 化学式: C₂₄H₃₇NO
• 分子量: 355.564
• InChiKey: IOIMWLSSNSWJLN-YVDNJGTBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.3
• 重原子数：
  26
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  维A酸 在 三氯化磷 作用下， 以 苯 为溶剂， 反应 4.75h， 生成 (2Z,4E,6Z,8Z)-N-丁基-3,7-二甲基-9-(2,6,6-三甲基-1-环己烯基)壬-2,4,6,8-四烯酰胺
  参考文献：
  名称：

  某些13-顺式和全反式视黄酰胺的合成和性质

  摘要：

  通过13-顺-视黄酰氯或13-顺-1-视黄基咪唑从13-顺-视黄酸合成了几种13-顺-视黄酰胺。由全反式视黄酰氯和甘氨酸乙酯制备全反式视黄酰甘氨酸。开发了用于制备其他全反式维甲酸酰胺的详细程序，以用于癌症化学预防的研究。

  DOI：

  10.1002/jps.2600730610

文献信息

• Method to incorporate N-(4-hydroxyphenyl) retinamide in liposomes
  申请人：Board of Regents, The University of Texas System

  公开号：US20020143062A1

  公开（公告）日：2002-10-03

  Disclosed herein are simple and unique methods of methods of preparing liposomal compositions of N-(4-hydroxyphenyl) retinamide (4HPR) and/or other retinoids. Also disclosed are liposomal 4HPR compositions prepared by such methods, and use of such compositions in the treatment of diseases, such as breast cancer. This invention further provides methods for improving the efficacy of N-(4-hydroxyphenyl) retinamide (4HPR) as a chemopreventive agent in the presence of agents that potentiates its ability increase the expression of inducible nitric oxide synthase (iNOS, and NO production in cells.

  本文披露了制备N-(4-羟基苯基)视黄酰胺（4HPR）和/或其他视黄醇脂质体组合物的简单且独特的方法。还披露了通过这些方法制备的脂质体4HPR组合物，并将这种组合物用于治疗疾病，如乳腺癌。本发明还提供了一种方法，通过增强诱导型一氧化氮合酶（iNOS）和细胞内NO产生的能力，提高N-(4-羟基苯基)视黄酰胺（4HPR）作为化学预防剂的功效。
• Amino, Amino Acid or Peptide Conjugates of Retinoic Acid
  申请人：Beumer Raphael

  公开号：US20070270472A1

  公开（公告）日：2007-11-22

  The invention provides the use of retinoyl derivatives for the cosmetic treatment or prophylaxis of wrinkles, skin aging and/or for thickening the epidermis.

  本发明提供了利用维甲酸酯类化合物进行美容治疗或预防皱纹、皮肤老化和/或增厚表皮的方法。
• CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS
  申请人：Nitto Denko Corporation

  公开号：US20140294934A1

  公开（公告）日：2014-10-02

  Here described are compounds of formula I: wherein R 1 and R 2 is independently selected from a group consisting of C 10 to C 18 alkyl, C 12 to C 18 alkenyl, and oleyl group; wherein R 3 and R 4 are independently selected from a group consisting of C 1 to C 6 alkyl, and C 2 to C 6 alkanol; wherein X is selected from a group consisting of —CH 2 —, —S—, and —O— or absent; wherein Y is selected from —(CH 2 ) n , —S(CH 2 ) n , —O(CH 2 ) n —, thiophene, —SO 2 (CH 2 ) n —, and ester, wherein n=1-4; wherein a=1-4; wherein b=1-4; wherein c=1-4; and wherein Z is a counterion; as well as compositions and pharmaceutical formulations including compounds of formula I which are useful for the delivery of therapeutic agents; and methods of using these compositions and formulations.

  这里描述的是I式化合物，其中R1和R2独立地选自由C10到C18烷基、C12到C18烯基和油酰基组成的一组；R3和R4独立地选自由C1到C6烷基和C2到C6醇基组成的一组；X选自由—CH2—、—S—和—O—或不存在的一组；Y选自由—(CH2)n、—S(CH2)n、—O(CH2)n—、噻吩、—SO2(CH2)n—和酯组成的一组，其中n=1-4；a=1-4；b=1-4；c=1-4；Z是一个计数离子；以及包括I式化合物的组合物和制药配方，这些化合物对于传递治疗剂是有用的；以及使用这些组合物和配方的方法。
• TARGETING AGENT FOR CANCER CELL OR CANCER-ASSOCIATED FIBROBLAST
  申请人：Nitto Denko Corporation

  公开号：US20130210744A1

  公开（公告）日：2013-08-15

  Disclosed are a novel therapeutic agent and a novel treatment method for cancer. Specifically disclosed are: a targeting agent for a cell selected from the group consisting of a cancer cell and a cancer-associated fibroblast, which comprises a retinoid and/or derivative thereof; a substance delivery carrier for the cell, which comprises the targeting agent; an anti-cancer composition utilizing the targeting agent or the carrier; an anticancer-associated fibroblast composition; and a method for treatment of cancer.

  本发明涉及一种新的治疗剂和癌症的新治疗方法。具体涉及的是：一种针对癌细胞和癌相关成纤维细胞中所选细胞的靶向剂，包括维甲酸和/或其衍生物；一种用于该细胞的物质传递载体，包括靶向剂；一种利用靶向剂或载体的抗癌组合物；一种抗癌相关成纤维细胞组合物；以及一种癌症治疗方法。
• Cationic Lipids for Therapeutic Agent Delivery Formulations
  申请人：Nitto Denko Corporation

  公开号：US20160137593A1

  公开（公告）日：2016-05-19

  Here described are compounds of formula I: wherein R 1 and R 2 are independently selected from C 10 to C 18 alkyl, C 12 to C 18 alkenyl, and oleoyl; R 3 and R 4 are independently selected from C 1 to C 6 alkyl and C 2 to C 6 alkanol; X is selected from —CH 2 —, —S—, and —O—, or X is absent; Y is selected from —(CH 2 ) n , —S(CH 2 ) n —, —O(CH 2 ) n —, -thiophene-, —SO 2 (CH 2 ) n —, and ester; n=1-4; a=1-4; b=1-4; c=1-4; and Z − is a counterion. Also described herein are compositions and pharmaceutical formulations including compounds of formula I which are useful for the delivery of therapeutic agents, and methods of using these compositions and formulations.

  本文描述了公式I的化合物：其中R1和R2独立选择自C10到C18烷基，C12到C18烯基和油酰基; R3和R4独立选择自C1到C6烷基和C2到C6醇基; X从—CH2—，—S—和—O—中选择，或X不存在; Y从—(CH2)n，—S(CH2)n—，—O(CH2)n—，-噻吩-，—SO2(CH2)n—和酯中选择; n=1-4; a=1-4; b=1-4; c=1-4; Z-是计数离子。本文还描述了包括公式I化合物的组合物和制药配方，这些化合物对于输送治疗剂是有用的，以及使用这些组合物和配方的方法。